These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21248172)

  • 1. Targeting macrophages in classical Hodgkin's lymphoma may seem rational, but is it safe?
    Dasanu CA
    J Oncol Pharm Pract; 2012 Mar; 18(1):104-8. PubMed ID: 21248172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.
    Aldinucci D; Gloghini A; Pinto A; De Filippi R; Carbone A
    J Pathol; 2010 Jul; 221(3):248-63. PubMed ID: 20527019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD30 expression utilization for the accuracy of classical Hodgkin's lymphoma staging.
    Flangea C; Potencz E; Mihăescu R; Anghel A; Gîju S; Motoc M; Dogaru C
    Rom J Morphol Embryol; 2006; 47(2):113-7. PubMed ID: 17106517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic impact of tumour-associated macrophages and Reed-Sternberg cells in paediatric Hodgkin lymphoma.
    Gupta S; Yeh S; Chami R; Punnett A; Chung C
    Eur J Cancer; 2013 Oct; 49(15):3255-61. PubMed ID: 23791542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
    Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
    Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hodgkin's lymphoma: the role of cell surface receptors in regulation of tumor cell fate.
    Yurchenko M; Sidorenko SP
    Exp Oncol; 2010 Dec; 32(4):214-23. PubMed ID: 21270747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.
    Carlo-Stella C; Santoro A
    Biomark Med; 2015; 9(8):807-17. PubMed ID: 26223461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
    Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
    Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.
    Ishida T; Ishii T; Inagaki A; Yano H; Kusumoto S; Ri M; Komatsu H; Iida S; Inagaki H; Ueda R
    Leukemia; 2006 Dec; 20(12):2162-8. PubMed ID: 17039235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bauhinia purpurea--a new paraffin section marker for Reed-Sternberg cells of Hodgkin's disease. A comparison with Leu-M1 (CD15), LN2 (CD74), peanut agglutinin, and Ber-H2 (CD30).
    Sarker AB; Akagi T; Jeon HJ; Miyake K; Murakami I; Yoshino T; Takahashi K; Nose S
    Am J Pathol; 1992 Jul; 141(1):19-23. PubMed ID: 1352944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of an Mr 70,000 antigen associated with Reed-Sternberg cells and interdigitating reticulum cells.
    Hsu PL; Hsu SM
    Cancer Res; 1990 Jan; 50(2):350-7. PubMed ID: 2153049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.
    Schnell R; Dietlein M; Staak JO; Borchmann P; Schomaecker K; Fischer T; Eschner W; Hansen H; Morschhauser F; Schicha H; Diehl V; Raubitschek A; Engert A
    J Clin Oncol; 2005 Jul; 23(21):4669-78. PubMed ID: 16034043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune reactions in classical Hodgkin's lymphoma.
    Poppema S; Potters M; Emmens R; Visser L; van den Berg A
    Semin Hematol; 1999 Jul; 36(3):253-9. PubMed ID: 10462325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody-based immunotherapy of Hodgkin's lymphoma.
    Borchmann P; Schnell R; Schulz H; Engert A
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1262-7. PubMed ID: 15648946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunopathology of Hodgkin's disease. Characterization of Reed-Sternberg cells with monoclonal antibodies.
    Strauchen JA; Dimitriu-Bona A
    Am J Pathol; 1986 May; 123(2):293-300. PubMed ID: 3085509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
    Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
    Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMA monoclonal antibody is a superior anti-CD15 reagent for the diagnosis of classical Hodgkin's lymphoma?
    Pellegrini W; Bresciani G; De Zorzi A; Marocolo D; Ungari M; Facchetti F
    Haematologica; 2007 May; 92(5):708-9. PubMed ID: 17488702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells.
    Hummel M; Ziemann K; Lammert H; Pileri S; Sabattini E; Stein H
    N Engl J Med; 1995 Oct; 333(14):901-6. PubMed ID: 7545266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas.
    Miettinen M
    Arch Pathol Lab Med; 1992 Nov; 116(11):1197-201. PubMed ID: 1332642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma.
    Gerber HP
    Biochem Pharmacol; 2010 Jun; 79(11):1544-52. PubMed ID: 20096666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.